Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical, Inc. (OHRP) is a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases. The company has completed two clinical trials with squalamine lactate ophthalmic solution, 0.2%, for the treatment of the wet form of age-related macular degeneration.  In addition, Ohr has a sustained-release micro-fabricated micro-particle ocular drug delivery platform technology.


Bank Name Ohr Pharmaceutical, Inc.
Stock Exchange NASDAQ
Symbol OHRP
Sector Healthcare
Industry Major Pharmaceuticals
Country United States
World Region Amarica
CEO Dr. Jason Scott Slakter
Employees 4
Website www.ohrpharmaceutical.com
Registered Year